Similar Prognosis of Patients with Bone-only Metastatic Breast Cancer and Visceral Metastasis

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 91

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_ARCHB-8-1_010

تاریخ نمایه سازی: 9 آبان 1401

Abstract:

Background: Bone-only metastatic breast cancer is believed to be non-lifethreatening,and mild therapy is frequently selected to avoid adverse events of drugtherapy. However, the prognoses of such patients are not well studied.Methods: Patients who received drug therapies for metastatic breast cancerbetween ۲۰۰۴ and ۲۰۱۶ at our institution were divided into the “Bone-onlymetastasis”, “non-visceral”, and “visceral” groups based on the mode of the firstmetastasis, and the efficacy of the first-line therapy and survival of these patientswere compared.Results: There were ۱۳۱ eligible patients, and the bone-only metastasis, nonvisceral,and visceral groups included ۲۶, ۲۵, and ۸۰ patients, respectively. Themedian survival time (MST) of the overall survival (OS) in each group was ۳۵.۱,۳۴.۹, and ۳۷.۴ months, respectively (p=۰.۷۱). The clinical benefit rates of first-linetherapy in the bone-only metastasis, non-visceral, and visceral groups were ۶۶.۷%,۴۵%, and ۶۹.۳%, respectively, and the MST of the time to treatment failure (TTF)in each group was ۶.۳, ۵.۵, and ۵.۸ months, respectively, showing that the efficacyof first-line therapy did not significantly differ among the groups. In the bone-onlymetastasis group, patients with <۵ metastases tended to have a good prognosis, andthose with a low nuclear grade and long first-line therapy duration had asignificantly better prognosis than others.Conclusion: The patients with bone-only metastasis had a similar prognosisand treatment response to those with other modes of metastasis, and the patientswith a good response to the first-line therapy had a good prognosis.

Authors

Ryutaro Mori

Department of Surgical Oncology, Gifu University Graduate School of Medicine, ۱-۱ Yanagido,۵۰۱-۱۱۹۴, Gifu, Japan

Manabu Futamura

Department of Surgical Oncology, Gifu University Graduate School of Medicine, ۱-۱ Yanagido,۵۰۱-۱۱۹۴, Gifu, Japan

Yoshimi Asano

Department of Surgical Oncology, Gifu University Graduate School of Medicine, ۱-۱ Yanagido,۵۰۱-۱۱۹۴, Gifu, Japan

Akira Nakakami

Department of Surgical Oncology, Gifu University Graduate School of Medicine, ۱-۱ Yanagido,۵۰۱-۱۱۹۴, Gifu, Japan

Kazuhiro Yoshida

Department of Surgical Oncology, Gifu University Graduate School of Medicine, ۱-۱ Yanagido, ۵۰۱-۱۱۹۴, Gifu, Japan